Navigating Emerging Therapeutics: How Mikart Supports Cannabinoid and Psilocybin Drug Development
As the pharmaceutical industry evolves, the exploration of alternative and plant-derived therapies has moved from the fringe to the forefront...
Liquid Suspension Trends in the CDMO Space
In recent years, the pharmaceutical industry has witnessed a significant shift towards liquid suspension formulations, particularly within the Contract Development...
Accelerating Product Development with Mikart’s Non-GMP Small-Scale Laboratory
8 Laboratory Suites Available In the highly competitive pharmaceutical industry, speed is everything. The faster a product can move from...
Sailing Smoothly: Partnering with a CDMO for Liquid-Oral Formulation Development
Liquid-oral formulations, from solutions to syrups, come with their fair share of complexities. Think solubility woes, stability concerns, and taste...
The Crucial Role of Project Managers in Selecting a CDMO Partner
In the fast-paced and highly competitive landscape of pharmaceutical development and manufacturing, the role of project managers cannot be overstated....
On the Journey to Support Drug Developers With End-to-End Outsourcing
Mikart, an oral dosage focused contract development and manufacturing organization (CDMO), is moving beyond generic manufacturing to support customers from...
Unapproved Drugs Initiative
The Unapproved Drugs Initiative (UDI) is a program launched by the Food and Drug Administration (FDA) in 2006 to remove...
Phase Appropriate Analytical Method Development and Validation
A critical component of the development process for investigational new drugs (INDs) is the establishment of clear, purposeful analytical methods...
Our new website has launched
We are so pleased to announce the launch of our new website! We are excited to have launched our new...
Mikart continues to meet the growing demand for the development and manufacturing of controlled substances
There continues to be a big need for new molecules of the medical importance of controlled substances that specifically address...